Astria Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview

Astria Therapeutics

20/03/2023 12:58

* Astria Therapeutics Inc  ATXS.OQ   ATXS.O  is expected
to show
no change in quarterly revenue when it reports  results on March
22. 
    * 
    * ​Refinitiv's mean analyst estimate for Astria Therapeutics
Inc
is for a loss of 71 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Astria
Therapeutics Inc is $25​, above​ its last closing price
of $11.40. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.91       -0.92      -0.87     Beat    5.2
 Jun. 30 2022  -0.99       -1.01      -0.86     Beat    15.3
 Mar. 31 2022  -0.72       -0.73      -1.18     Missed  -62.1​
 Dec. 31 2021  -0.68       -0.66      -11.00    Missed  -1,566
                                                        .7
 ​​Sep.        -0.76       -0.77      -0.61     Beat    21
 30 2021                                                
 Jun. 30 2021  -1.88       -1.82      -1.26     Beat    30.8​
 Mar. 31 2021  -0.86       -0.92      -1.44     Missed  -56.5
 Dec. 31 2020  -2.04       -2.22      -2.64     Missed  -18.9
 This summary was machine generated March 20 at 12:58 GMT.  All
figures in US dollars  unless otherwise stated